Item 8.01 Other Events.

On November 29, 2021, Sigilon Therapeutics, Inc. (the "Company") provided an update on the Company's Phase 1/2 clinical trial of SIG-001 in hemophilia A, which is on clinical hold. The Company issued a press release reporting that fibrosed spheres were observed during a retrieval procedure in a patient dosed in the study, which is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits


Exhibit
  No.       Description
              Press Release Issued by Sigilon Therapeutics, Inc. on November 29,
99.1        2021
            Cover Page Interactive Data File (embedded within the Inline XBRL
104         document)

© Edgar Online, source Glimpses